Cellectis S.A.

ALCLS

FR0010425595

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:55:00 07/07/2025 BST			5-day change	1st Jan Change
1.366 ^EUR	-2.29%		+6.72%	-16.20%

07-07	European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	MT
07-03	European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading	MT

European Equities Traded in the US as American Depositary Receipts Advance Wednesday

Published on 04/06/2025 at 16:19

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Cellectis S.A.

European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	07-07	MT
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading	07-03	MT
Cellectis Proposes $200 Million Mixed Shelf Offering	07-02	MT
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	07-02	MT
European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading	07-01	MT
Cellectis S.A. Announces Board Changes	06-26	CI
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	06-26	MT
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	06-24	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06-16	MT
European Equities Traded in the US as American Depositary Receipts Slide Friday	06-13	MT
European Equities Traded in the US as American Depositary Receipts Advance Wednesday	06-04	MT
European Equities Traded in the US as American Depositary Receipts Modestly Higher in Thursday Trading	05-29	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; End Week Lower	05-23	MT
Cellectis S.A. Announces Resignation of Pierre Bastid from the Board of Directors, Effective June 26, 2025	05-21	CI
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	05-20	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	05-19	MT
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up 1.4% for Week	05-16	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	05-15	MT
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading	05-13	MT
Cellectis S.A. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-12	CI
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	05-12	MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	05-07	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	05-06	MT
European Equities Traded in the US as American Depositary Receipts Marginally Higher in Monday Trading	05-05	MT
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading	05-01	MT

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR T cells for the treatment of cancer patients, and a platform for for the development of gene therapies in other therapeutic indications. Thanks to its fully in-house production capabilities, Cellectis S.A. is one of the few genome-editing companies to control the cell and gene therapy value chain from end to end.

Employees

219

Sector

Biotechnology & Medical Research

Calendar

07-14 - Cell Therapies Process Development Summit

More about the company